Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer.

ABSTRACT:

Background

trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contribute to trastuzumab resistance through AKT activation. An association between adenine thymine-rich interactive domain 1A (ARID1A) loss and ANXA1 upregulation was also previously suggested by others.

Methods

in this study, we examined tissue samples from 215 HER-2+ breast cancer patients to in

SUBMITTER: Silva-Oliveira R 

PROVIDER: S-EPMC7761245 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature